Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Crucell and Harvard Join Forces with IAVI
Volgen
z0n0p schreef:
....Niet zo somberen! Kijk naar het rendement op je aandelen in de laatste 1,5 jaar > 50%. ...
Laatste 1,5 jaar? Waarom geen 1, 3, of 4 jaar? 'n Beetje de meest gunstige periode cherrypicken. Je lijkt RonB wel ;-)
tip: lees de diverse rapporten in de periode 2005/2006 nog eens door van diverse brokers / analisten. Lig je nu , helemaal dubbel .
wilb52 schreef:
tip:
lees de diverse rapporten in de periode 2005/2006
nog eens door van diverse brokers / analisten.
Lig je nu , helemaal dubbel .
Ken je Marcel - "Alles onder €18 is een KOOPJE" - Wijma nog!
Zullen we het veranderen naar Alles onder de 15.56 is een koopje?!
Dat meen je niet, ik heb past verkocht :-((
Heb ik die op 15.45 dan van jou gekocht? Voor de gok op goede cijfers, trouwens dat interesseert me verder geen bal, als de koers maar omhoog gaat, zodat ze liefst met forse winst weer weg kunnen, voor bezoek aan de Aldi, Lidl en niet te vergeten , ter financiering van mijn komende vakantie. Zijn jullie weer even van me af, dus CruSELL , hup Crucell hup, up me du gijt, upupup. (:->D)
1. The Ad26.ENVA.01 vaccine candidate used in this study is manufactured by Crucell, while the Ad35-ENV vaccine is developed by International AIDS Vaccine Initiative (IAVI). Both vaccines candidates are based on Crucell's proprietary AdVac® technology. A.Wat mij hierbij opvalt dat bovengenoemde vaccines beiden gebaseerd zijn op de AdVac® technologie van Crucell. International AIDS Vaccine Initiative (IAVI) , vanaf Sep. 2004, voor AdVac® tegen HIV. 2.The clinical trial, which will be led by the International AIDS Vaccine Initiative (IAVI), represents a collaboration between 1e IAVI, 2e Crucell, 3e the Ragon Institute, 4e and Beth Israel Deaconess Medical Center (BIDMC), a major teaching hospital of Harvard Medical School. B. Wat mij hierbij opvalt dat er 4 partijen bij betrokken zijn. 3.Crucell today (11-8-2010) announces its intention to participate in an international Phase I clinical trial in the United States and Africa of a combination of two AdVac®-based AIDS vaccine candidates, Ad26.ENVA.01 and Ad35-ENV, in healthy adults who are not infected with HIV. C. Wat mij hierbij opvalt is dat de clinical trial zowel plaats gaat vinden in de Verenigde Staten als in Afrika.
@JAR51: ter aanvulling. Fast Facts Crucell and the International AIDS Vaccine Initiative (IAVI) jointly announced an agreement in November 2004, in which Crucell agreed to develop AdVac® vectors for use in IAVI's AIDS vaccine development program. In August 2005, Crucell and Harvard Medical School were jointly awarded a US$19.2 million (€15.9 million) grant by the US National Institutes of Health (NIH) to develop new adenovirus vector-based vaccines against HIV/AIDS. The Investigational New Drug Application (IND) for Phase I of the trial with Harvard Medical School (supported by the NIH) was approved by the FDA in January 2008. In April 2008, Crucell announced the start of a Phase I clinical study of the novel recombinant HIV vaccine (using adenovirus serotype 26 (rAd26) as the vector) that we are jointly developing with the Beth Israel Deaconess Medical Center. In October 2009, preliminary results of the Phase I study were presented at La Conférence AIDS Vaccine 2009 in Paris, France. They showed that a 3 dose regimen with this HIV candidate vaccine is safe and immunogenic. Phase I clinical studies are being conducted at the Brigham and Women's Hospital in Boston, USA and are focused on assessing the safety and immunogenicity of the vaccine in several trials including single and multi-dose regimens.www.crucell.com/R_and_D-Clinical_Deve... Vaccines based on the AdVac® technology belong to the second generation of vaccines, comprising Ad11-, Ad35-, and Ad49-based vectors and derivatives thereof. Since pre-existing immunity against these vectors is very limited, they allow effective delivery of small fragments of otherwise deadly pathogens to the immune system using a replication incompetent adenovirus vehicle. AdVac® vaccination vectors can be manufactured to high titers on a PER.C6® cell substrate. AdVac® vectors combine all the advantages of the commonly used adenovirus vector for vaccination, such as high production yields, strong immunogenicity and an excellent safety profile, together with accurate dose control of the vector-based vaccine. Thus, Crucell’s AdVac®-based vaccines are expected to deliver consistent results in clinical studies. AdVac® technology for highly immunogenic vaccines AdVac®-based vaccines for malaria, AIDS, hepatitis C, hemorraghic fevers, and tuberculosis have been successfully constructed and have been tested in pre-clinical vaccine models. Strong CD4 and CD8 T-cell responses were elicited by the AdVac®-based vaccines as well as potent and neutralizing antibody responses. In all instances, the high immune response elicited upon vaccination against the pathogenic antigens resulted in completed protection of the vaccinated animals upon high dose challenge demonstrating the strengths of AdVac® vectors. AdVac® vector-based products from bench to clinic Crucell has fully operational BSL-II laboratories with integrated upstream and downstream capacities up to a 10L scale. These units are used to develop purification methods closely resembling an end-stage manufacturing process. With this facility, Crucell has the ability to manufacture Ad11 or Ad35 vaccine vectors for comprehensive pre-clinical programs. Crucell has a fully operational GMP facility that has been designed as a multi-purpose production plant, which allows for the production of clinical-grade vaccines based on live vectors such as recombinant adenovirus. These products can be manufactured using PER.C6® technology under serum-free conditions in formats ranging from roller bottles to bioreactors. Crucell is expanding the GMP production capacity to 100L working volumes. __ Improving the Gene Delivery Technology for Vaccination Leiden, The Netherlands, June 1, 2001 Crucell and Harvard Medical School Announce Promising Results for Novel Vaccine Technology (AdVac®) Vaccine vectors overcome pre-existing immunity to rAd5 Leiden, The Netherlands, August 30, 2004 Crucell Grants IAVI Exclusive License to use AdVac® Technology for AIDS Vaccine Leiden, The Netherlands, September 14, 2004 Crucell Signs Agreement with IAVI to Develop AdVac® Vector for AIDS Vaccine Program Leiden, The Netherlands, November 12, 2004 Harvard and Crucell Receive $19.2 million NIH Grant to Develop Next-Generation AdVac®-based Vaccines Leiden, The Netherlands, August 1, 2005 Crucell Secures $16.2 million NIH Contract for HIV Vaccine Design and Development Leiden, The Netherlands, October 9, 2006 Crucell Announces First in Man Study with New Adenovirus Vector Recombinant adenovirus 26 vector avoids pre-existing immunity and is used in new HIV vaccine Leiden, The Netherlands, 3 April 2008 Crucell HIV Vaccine: Promising Preliminary Results Phase I Study Presented by Dr Dan Barouch at AIDS Vaccine 2009 in Paris Leiden, The Netherlands (October 21, 2009)www.crucell.com/News%20-%20Press%20Re... IAVI Grants Harvard Researchers License To Use AIDS Vaccine Production Technology 16 Mar 2006 New York / Boston, March 16, 2006 - The International AIDS Vaccine Initiative (IAVI) and Beth Israel Deaconess Medical Center (BIDMC) jointly announced an agreement whereby IAVI will provide BIDMC researchers with a non-exclusive, non-commercial research and development license to use AdVac® technology, an adenovirus-based vaccine production technology, for AIDS vaccine development.www.iavi.org/news-center/Pages/PressR... Ad35-GRIN/ENV A—An Ad35-based AIDS vaccine candidate (USA): This Phase I trial, launched in collaboration with the University of Rochester Medical Center, aims to evaluate the safety and immunogenicity of an AIDS vaccine candidate based on serotype 35 of the adenovirus (Ad35).www.iavi.org/research-development/tri... clinicaltrials.gov/ct2/show/NCT00851383 Two Phase I Trials Launched … IAVI is also planning to begin enrolling volunteers in a Phase I trial of its adenovirus serotype 35 (Ad35)-based vaccine candidate. The trial will enroll 42 volunteers at the University of Rochester Medical Center who will be randomly selected to receive either two intramuscular injections of the Ad35-based vaccine candidate or placebo at three different doses. Clinicians will first administer the lowest dose and will review the safety data before proceeding to the next higher dose. Ad35 is a serotype or strain of the common cold virus that researchers are using as a vaccine vector in this candidate to shuttle non-harmful fragments of clade A HIV, which is the predominant strain circulating in East Africa. The prevalence of naturally circulating Ad35 is much lower worldwide than the prevalence of adenovirus serotype 5, which was the virus used as a vector in Merck's AIDS vaccine candidate that was tested in the STEP trial. By using Ad35, it may be possible to circumvent issues involving pre-existing immunity to the viral vector www.iavireport.org/vax/2009/Pages/IAV... Understanding Pre-existing Immunity www.iavireport.org/vax-primers/scienc...
Adenovirus 35: Work on candidates based on alternative adenovirus vectors is exciting because it offers the possibility of a fast track to testing effectiveness in a Phase IIb trial. Adeno vectors are easily manufactured, immunogenic and have a good track record on side effects. IAVI and partners are testing an AIDS vaccine candidate based on adenovirus type 35 (Ad35) in a Phase I trial. Adenoviruses have been popular vectors for AIDS vaccine development, but because many people have been exposed to common adenoviruses and thus have immunity to them, IAVI and partners are pursuing a platform based on the rare type Ad35. In the current tests, two different Ad35 vaccine candidates have been created, each containing different genetic components of HIV. The goal is to assess safety and see whether one component prompts a stronger immune response than the other, and to understand a broader range of biological reactions to components of HIV in humans. Data from this trial will inform a possible progression to a new trial using adenovirus vectors in a prime-boost strategy, which has shown promising results in animal models.www.iavi.org/research-development/Doc... Draadje HIV: www.iex.nl/forum/topic.asp?forum=228&...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
Nextensa
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
918,72
-0,64%
EUR/USD
1,0706
0,00%
FTSE 100
8.146,86
-0,21%
Germany40^
18.004,30
-1,43%
Gold spot
2.332,68
0,00%
NY-Nasdaq Composite
17.688,88
+0,12%
Stijgers
Dalers